XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies - Novartis Option and License Agreement (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 01, 2023
USD ($)
item
Mar. 04, 2022
USD ($)
item
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
item
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration revenue | $         $ 150,480 $ 658
Related party collaboration receivable | $     $ 328 $ 257 328  
Novartis Pharma, AG | Novartis License Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of transgenes   3        
Number of additional targets 2 2        
Upfront payment | $ $ 54,000 $ 54,000 25,000      
Additional fee agreed to pay | $ $ 18,000          
Number of royalties 2          
Exercise payment | $ $ 25,000          
Number of targets not elected to license a capsid 1          
Aggregate milestone payments, if exercise rights | $ $ 12,500          
Number of license options       2    
Number of license option exercise for each target   1        
Number of Alliance Managers   2        
Number of options   1        
Number of major market countries received regulatory approval   3        
Number of days written notice required by reporting entity to terminate agreement 90 days          
Number of performance obligations   3        
Number of material rights   3        
Allocation of transaction price | $   $ 18,000        
Novartis Pharma, AG | Novartis License Agreement | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of license options   3        
Novartis Pharma, AG | Novartis License Agreement | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of license options   5        
Novartis Pharma, AG | Option and license agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Exercise payment | $         25,000  
Revenue recognized | $         79,000  
Collaboration revenue | $         79,000  
Related party collaboration receivable | $     $ 25,000   $ 25,000  
Novartis Pharma, AG | First Material Right            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment | $       $ 54,000